AZD3480, a Novel Nicotinic Receptor Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

  title={AZD3480, a Novel Nicotinic Receptor Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults},
  author={Alexandra S. Potter and Geoffrey C. Dunbar and Emily C. Mazzulla and David A. Hosford and Paul A. Newhouse},
  journal={Biological Psychiatry},

Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date

Attention-deficit/hyperactivity disorder symptoms were reduced in the majority of published studies of nicotine and novel α4β2 nicotinic agonists in adult ADHD, and targeting nAChRs in ADHD appears to have a modest clinical benefit inAdult ADHD.

Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder

This article reviews Phase I and Phase II trials of sofinicline (ABT-894), an agonist of the nAChR α4β2 subtype, as a potential non-stimulant treatment for ADHD and finds it to be well tolerated and showing efficacy similar to that of atomoxetine.

Pozanicline for the treatment of attention-deficit/hyperactivity disorder

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder occurring in childhood and often continues into adolescence and adulthood. The

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

A review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years for the pharmacological treatment of ADHD found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients.

Alternative pharmacological strategies for adult ADHD treatment: a systematic review

Among alternative compounds, amphetamines have the most robust evidence of efficacy, but they may be associated with serious side effects (e.g. psychotic symptoms or hypertension), and antidepressants, particularly those acting as noradrenaline or dopamine enhancers, have evidence of effective but should be avoided in patients with comorbid bipolar disorder.

Treatments and compositions for attention deficit hyperactivity disorder: a patent review

This review emphasizes the recent progress in ADHD treatment, which was published in the patent literature from 2005-2015, and focused on novel mechanisms of action and potential treatments for achieving control of ADHD comorbidities, offering theoretical advantages compared with current medication.

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders.

Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system

Findings support the hypotheses that the nicotinic cholinergic system modulates social and repetitive behaviors and may be a therapeutic target to treat behavior deficits in ASD.

Effects of lisdexamfetamine alone and in combination with s‐citalopram on acetylcholine and histamine efflux in the rat pre‐frontal cortex and ventral hippocampus

Results suggest that efflux of acetylcholine and histamine may be involved in the therapeutic effects of LDX and are differentially influenced by the co‐administration of s‐citalopram.



A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder.

The results of this investigation indicate that ABT-418, a nicotinic analog, may be a potentially useful agent for the treatment of ADHD.

Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

In this phase 2 crossover study, the NNR partial agonist ABT-089, at doses of 40 mg QD and 40-mg BID, was efficacious and generally well tolerated in treatment of adults with ADHD.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

DMXB-A, a nicotinic agonist that activates alpha(7)-nicotinic receptors, improved clinical ratings of negative symptoms that are generally resistant to treatment with dopamine antagonist antipsychotic drugs.

A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder

The results of this study support previous research indicating that nicotinic receptor modulation may be a potentially useful strategy for the treatment of ADHD, and therapeutic uses of nicotine are limited due to side effects.

Effects of nicotinic stimulation on cognitive performance.

A review of the pharmacotherapy of adults with Attention-Deficit/ Hyperactivity Disorder

Under controlled conditions, the aggregate literature shows that the stimulants and noradrenergic antidepressants had a clinically and statistically significant beneficial effect on treating ADHD in adults.

An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder.

Results of this small open study suggest that donepezil augmentation of stimulants is not well tolerated and does not appear useful for the treatment of residual ADHD and/or EF deficits.

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

Early results demonstrate ispronicline was well tolerated and did not display the side effects typical of nicotine, and was seen most strongly in a Cmax range that had been predicted from pre-clinical animal studies.